{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-002744","form_type":"8-K","ticker":"ZOMDF","cik":"0001684144","company_name":"Zomedica Corp.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.437074+00:00","generated_at":"2026-05-24T18:36:43.380214+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Zomedica reports record Q4 revenue $7.9M, full year $27.3M; net loss narrows to $7.2M","bullets":["Q4 2024 revenue $7.9M (+8% YoY); full year $27.3M, also up 8% from 2023.","Gross margin 70.3% for Q4 and 70.0% for full year, at high end of 65-70% guidance.","Net loss improved to $7.2M in Q4 from $22.4M a year ago; full year net loss $47.0M vs $34.5M.","Diagnostics segment revenue surged 109% YoY in Q4 driven by TRUFORMA and VETGuardian adoption.","Cash, equivalents and securities $71.4M; adjusted non-GAAP EBITDA loss $20.2M for full year."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-002744","json":"https://secwatch.observer/filing/0001654954-25-002744.json","markdown":"https://secwatch.observer/filing/0001654954-25-002744.md","text":"https://secwatch.observer/filing/0001654954-25-002744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/0001654954-25-002744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/zom_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:36:43.380214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}